| 6253- | CBC/D, | The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma |
| - | Review, | MB, | NA |
| 6254- | CBC/D, | Cynanchum auriculatum Royle ex Wight., Cynanchum bungei Decne. and Cynanchum wilfordii (Maxim.) Hemsl.: Current Research and Prospects |
| - | Review, | Var, | NA |
| 17- | CBC/D, | CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1 |
| - | in-vivo, | CRC, | NA |
| 18- | CBC/D, | Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli |
| - | vitro+vivo, | MB, | NA |
| 1103- | CBD, | Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway |
| - | vitro+vivo, | NA, | NA |
| 5820- | CBD, | Cannabidiol effects in stem cells: A systematic review |
| - | Review, | Var, | NA |
| 5812- | CBD, | Cannabidiol oil or placebo in advanced cancer-disease progression and survival: a secondary analysis |
| - | Trial, | Var, | NA |
| 5813- | CBD, | Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis |
| - | Review, | Var, | NA |
| 5814- | CBD, | Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline |
| - | Review, | Var, | NA |
| 5815- | CBD, | Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents |
| - | in-vitro, | GBM, | NA |
| 5816- | CBD, | Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4 |
| - | in-vitro, | GBM, | NA |
| 5817- | CBD, | COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells |
| - | vitro+vivo, | Lung, | A549 |
| 5818- | CBD, | Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress |
| - | in-vivo, | PC, | PANC1 |
| 5819- | CBD, | The potential role of cannabidiol (CBD) in lung cancer therapy: a systematic review of preclinical and clinical evidence |
| - | Review, | Lung, | NA |
| 1199- | CBD, | Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis |
| - | in-vivo, | Obesity, | NA |
| 1081- | CBDA, | Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 5979- | CDT, | AgNPs, | Multifunctional nanomedicines-enabled chemodynamic-synergized multimodal tumor therapy via Fenton and Fenton-like reactions |
| - | Review, | Var, | NA |
| 5973- | CDT, | Chemodynamic Therapy via Fenton and Fenton-Like Nanomaterials: Strategies and Recent Advances |
| - | Review, | Var, | NA |
| 5974- | CDT, | Chemodynamic nanomaterials for cancer theranostics |
| - | Review, | Var, | NA |
| 5963- | CEL, | Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis |
| - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HepG2 |
| 5966- | CEL, | Determine whether administering celecoxib during radiotherapy can reduce the risk of recurrence of triple-negative breast cancer. Pilot study |
| - | Trial, | BC, | NA |
| 5965- | CEL, | Cisplatin, | Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway |
| - | in-vitro, | OS, | MG63 |
| 5964- | CEL, | Celecoxib pathways: pharmacokinetics and pharmacodynamics |
| - | Review, | Var, | NA |
| 5962- | CEL, | The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II |
| - | Study, | Var, | NA |
| 5961- | CEL, | Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer |
| - | Review, | Var, | NA |
| 5960- | CEL, | Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers |
| - | Trial, | Pca, | NA |
| 5959- | CEL, | Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target |
| - | in-vitro, | Cerv, | HeLa |
| 5958- | CEL, | Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition |
| - | in-vitro, | Var, | NA |
| 5957- | CEL, | Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line |
| - | in-vitro, | Colon, | HT29 |
| 5956- | CEL, | Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy |
| - | Review, | Var, | NA |
| 5955- | CEL, | COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib |
| - | in-vitro, | Colon, | NA |
| 5954- | CEL, | The molecular mechanisms of celecoxib in tumor development |
| - | Review, | Var, | NA |
| 1105- | CEL, | Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis |
| - | in-vitro, | BC, | NA |
| 1054- | CEL, | Celecoxib inhibited activation of NF-κB and expression of NF-κB P65 protein in HepG2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 955- | CEL, | Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells |
| - | in-vitro, | RPE, | D407 |
| 2653- | Cela, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2393- | Cela, | Celastrol mitigates inflammation in sepsis by inhibiting the PKM2-dependent Warburg effect |
| - | in-vivo, | Sepsis, | NA | - | in-vitro, | Nor, | RAW264.7 |
| 2392- | Cela, | The role of natural products targeting macrophage polarization in sepsis-induced lung injury |
| - | Review, | Sepsis, | NA |
| 5953- | Cela, | CUR, | The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis |
| - | vitro+vivo, | NPC, | NA |
| 5939- | Cela, | Chemo, | Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells |
| - | in-vitro, | Melanoma, | U266 | - | in-vitro, | Melanoma, | RPMI-8226 |
| 5938- | Cela, | Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application |
| - | Review, | Var, | NA |
| 5940- | Cela, | Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway |
| - | in-vivo, | Pca, | PC3 |
| 5941- | Cela, | Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 5942- | Cela, | Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | H460 | - | in-vitro, | NSCLC, | PC9 |
| 5952- | Cela, | Celastrol attenuates Alzheimer’s disease-mediated learning and memory impairment by inhibiting endoplasmic reticulum stress-induced inflammation and oxidative stress |
| - | in-vivo, | AD, | NA |
| 5943- | Cela, | Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases |
| - | Review, | Arthritis, | NA | - | Review, | IBD, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 5944- | Cela, | HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way |
| - | in-vitro, | AML, | U937 |
| 5945- | Cela, | Targeting the dynamic HSP90 complex in cancer |
| - | Review, | Var, | NA |
| 5946- | Cela, | The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer |
| - | in-vitro, | Var, | NA |
| 5947- | Cela, | Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid